Sugi Predict

Sugi Predict / Compounds / SCHEMBL12466875

SCHEMBL12466875

SCHEMBL12466875

NC(=O)c1cn2ccncc2n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 1/20 0.57
▸ CLK1 P49759 1/20 0.52
▸ DYRK1A Q13627 1/20 0.52
▸ ADORA3 P0DMS8 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ MC4R P32245 1/20 0.43
▸ ADRA1A P35348 1/20 0.43
▸ MC3R P41968 1/20 0.43
▸ ROCK1 Q13464 1/20 0.42
▸ PTGS1 P23219 1/20 0.40
▸ PTGS2 P35354 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ DRD2 P14416 2/20 0.36
▸ DRD3 P35462 2/20 0.36
▸ DRD4 P21917 1/20 0.36
▸ TGFBR1 P36897 3/20 0.36
▸ PDE3B Q13370 1/20 0.35
▸ PDE3A Q14432 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1812266 0.84 HRH4 (0.58) HRH4CLK1DYRK1AADORA3TSHR
SCHEMBL17324741 0.83 HRH4 (0.61) HRH4CLK1DYRK1AROCK1PTGS1
SCHEMBL8524119 0.83 HRH4 (0.50) HRH4CLK1DYRK1AROCK1PTGS1
SCHEMBL30980411 0.82 CYP1A2 (0.61) HRH4CLK1DYRK1AADORA3ROCK1
SCHEMBL31295445 0.79 HRH4 (0.51) HRH4CLK1DYRK1AROCK1PTGS1
SCHEMBL17321412 0.79 HRH4 (0.57) HRH4CLK1DYRK1AROCK1PTGS1
SCHEMBL19997261 0.79 HRH4 (0.57) HRH4CLK1DYRK1AROCK1PTGS1
SCHEMBL30828868 0.79 HRH4 (0.57) HRH4CLK1DYRK1AROCK1PTGS1
SCHEMBL8524121 0.76 CLK1 (0.46) HRH4CLK1DYRK1AADORA3TSHR
SCHEMBL2922016 0.75 KDM4E (0.63) HRH4CYP1A2MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612151-A1 PREPARATION OF IMIDAZOPYRIDINE AND IMIDAZOPYRIDAZINE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS Merck Sharp & Dohme LLC (US) 2025-09-10 — — EP claimed
WO-2024097573-A1 PREPARATION OF IMIDAZOPYRIDINE AND IMIDAZOPYRIDAZINE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-05-10 — — WO claimed
CN-111542523-B Heterocyclic compounds as PRMT5 inhibitors 朱比连特埃皮斯科瑞有限责任公司 2024-03-29 — — CN claimed
EP-4747255-A1 MODULATORS OF THE ADENOSINE A2A AND A2B RECEPTOR Ryvu Therapeutics S.A. (PL) 2026-05-27 — — EP disclosed
WO-2025018901-A1 MODULATORS OF THE ADENOSINE A2A AND A2B RECEPTOR Ryvu Therapeutics S.A. (PL) 2025-01-23 — — WO disclosed
CN-119095839-A Quinoline derivatives as modulators and related products of Mas-associated G protein receptor X2 伊赛恩特制药公司 2024-12-06 — — CN disclosed
CN-116730995-B Hydrazide compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2024-06-25 — — CN disclosed
CN-111542523-B Heterocyclic compounds as PRMT5 inhibitors 朱比连特埃皮斯科瑞有限责任公司 2024-03-29 — — CN disclosed
WO-2024032715-A1 HYDRAZIDE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF 深圳微芯生物科技股份有限公司 2024-02-15 — — WO disclosed
CN-116730995-A Hydrazide compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2023-09-12 — — CN disclosed
CN-116710434-A Modulators of MAS-related G protein receptor X2 and related products and uses thereof 伊赛恩特制药公司 2023-09-05 — — CN disclosed
WO-2016124564-A1 N-SUBSTITUTED 8-[(2,6-DIFLUOROBENZYL)OXY]-2,6-DIMETHYLIMIDAZO[1,2-A]PYRAZIN-3-CARBOXAMIDE DERIVATIVES AS STIMULATORS OF SOLUBLE GUANYLATE CYLASE (SGC) FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-08-11 — — WO disclosed
US-20160176880-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-06-23 — — US disclosed
US-20160176880-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-06-23 — — US disclosed
EP-3030564-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF Bayer Pharma Aktiengesellschaft (DE) 2016-06-15 — — EP disclosed
EP-3030564-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF Bayer Pharma Aktiengesellschaft (DE) 2016-06-15 — — EP disclosed
WO-2015018808-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-02-12 — — WO disclosed
WO-2015018808-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-02-12 — — WO disclosed
EP-2611804-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT Forma TM, LLC. (US) 2013-07-10 — — EP disclosed
WO-2012031197-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT FORMA THERAPEUTICS, INC. (US) 2012-03-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160176880-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF AADAC, PAICS, TPMT HRH4 210/4885CLK1 4034/4885DYRK1A 3433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.